Publications

Publications
Stay up to date with our most recent publications
All publications
  • Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion-optimized envelope trimmers as HIV-1 vaccine candidates
    Publications
    April 8, 2023 at 4:00 PM

    Uncleaved prefusion-optimized (UFO) design can stabilize diverse HIV-1 envelope glycoproteins (Envs). Single-component, self-assembling protein nanoparticles (1c-SApNP) can display 8 or 20 native-like Env trimers as vaccine candidates. We characterize the biophysical, structural, and antigenic properties of 1c-SApNPs that present the BG505 UFO trimer with wildtype and modified glycans.

    Learn more
  • Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
    Publications
    October 20, 2021 at 5:00 AM

    Vaccines that induce potent neutralizing antibody (NAb) responses against emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are essential for combating the coronavirus disease 2019 (COVID-19) pandemic.

    Learn more
  • Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines
    Publications
    May 11, 2021 at 3:00 AM
    The Ebola virus (EBOV) glycoprotein (GP) can be recognized by neutralizing antibodies (NAbs) and is the main target for vaccine design. We first investigated the contribution of the stalk and the heptad repeat 1-C (HR1C) region to GP metastability. Specifi...
    Learn more
  • Self-assembling nanoparticles presenting receptor binding domain and stabilized spike as next-gen COVID-19 vaccines
    Publications
    March 19, 2021 at 3:00 AM
    We present a comprehensive vaccine strategy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by combining antigen optimization and nanoparticle display. We first developed a receptor binding domain (RBD)-specific antibody column for purific...
    Learn more
  • Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines
    Publications
    April 15, 2020 at 5:00 AM

    Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are responsible for cell entry, with E2 being the major target of neutralizing antibodies (NAbs). Here, we present a comprehensive strategy for B cell–based HCV vaccine development through E2 optimization and nanoparticle display.

    Learn more
  • HIV-1 vaccine design through minimizing envelope metastability
    Publications
    November 21, 2018 at 6:00 AM

    Overcoming envelope metastability is crucial to trimer-based HIV-1 vaccine design. Here, we present a coherent vaccine strategy by minimizing metastability. For 10 strains across five clades, we demonstrate that the gp41 ectodomain (gp41ECTO) is the main source of envelope metastability by replacing wild-type gp41ECTO with BG505 gp41ECTO of the uncleaved prefusion-optimized (UFO) design.

    Learn more